safety and efficacy of aspirin in thromboprophylaxis after total hip arthroplasty: a retrospective study

Objectives: this study aimed to evaluate the safety and efficacy of aspirin as a standalone thromboprophylaxis (tp) treatment following elective total hip arthroplasty (tha). additionally, it compares the primary and secondary outcomes related to efficacy and safety, respectively, between aspirin and enoxaparin.methods: a retrospective review was conducted of 2,107 patients who underwent primary or revision total hip arthroplasty (tha) between 2011 and 2017. low-risk patients received aspirin (325 mg twice daily for 4 weeks), while high-risk patients were administered enoxaparin (4,000 units once daily for 2 weeks). the outcomes assessed included symptomatic deep vein thrombosis (dvt) or pulmonary embolism (pe), hematoma, bleeding, infection, and 90-day mortality.results: the incidence of symptomatic deep vein thrombosis (dvt) requiring treatment in the aspirin group was 0.10% (2/1,905), whereas no cases were observed in the enoxaparin group. the rate of fatal pulmonary embolism (pe) was 0.05% (1/1,905) in the aspirin group, compared to 0.49% (1/202) in the enoxaparin group. gastrointestinal (gi) bleeding occurred in 0.05% (1/1,905) of the aspirin group and 0.49% (1/202) of the enoxaparin group. the incidence of periprosthetic joint infection (pji) was 0.15% (3/1,905) in the aspirin group, compared to 0.49% (1/202) in the enoxaparin group.conclusion: as a standalone tp agent, aspirin is at least as effective as potent anticoagulants for patients undergoing elective tha, with comparable safety and efficacy profiles.